Delhi Police Issue Look‑Out Circular Against Dubai‑Based Indian in Rs 157 Crore Counterfeit Ozempic Case

The Delhi Police, invoking their statutory authority to safeguard public health, have issued a formal Look Out Circular against an Indian citizen presently domiciled in Dubai, alleging participation in a purportedly fraudulent scheme involving the counterfeit distribution of the anti‑diabetic medicine Ozempic, the alleged proceeds of which are reported to amount to an astonishing sum of one hundred and fifty‑seven crore rupees. The alleged operation, which ostensibly trafficked falsified injections purporting to emulate the genuine pharmaceutical formulation, is said to have targeted a broad urban clientele across the National Capital Region, thereby exposing unsuspecting patients to potentially hazardous health consequences while simultaneously undermining the credibility of the city’s regulatory oversight mechanisms. In response to the emerging scandal, the municipal health department has issued a series of advisories urging physicians and pharmacies to verify the authenticity of supplied insulin analogues, yet the department’s communications have been criticized for their delayed dissemination and for lacking the specific batch identifiers necessary to empower practitioners to discriminate effectively between legitimate and spurious consignments.

Furthermore, the city's procurement office, tasked with the vigilant supervision of drug import licences, appears to have allowed a conspicuous lapse in due‑diligence, as the alleged counterfeit consignments were ostensibly routed through a network of shell corporations whose registration documents bore only nominal ties to recognized Indian pharmaceutical firms. The public at large, already beset by the rising cost of chronic disease management, now confronts the added burden of navigating a labyrinthine complaints procedure that obliges victims to furnish exhaustive documentary proof, a requirement that many ordinary residents find both financially onerous and procedurally opaque.

The episode compels the municipal administration to confront the unsettling prospect that its existing pharmacovigilance framework may have been rendered ineffectual by procedural complacency, inter‑departmental miscommunication, and an overreliance on superficial compliance certifications that scarcely guarantee authentic product provenance. Consequently, one must inquire whether the licensing authority, charged with rigorous verification of overseas manufacturers, exercised statutory discretion with requisite diligence, or whether inter‑agency protocols for cross‑border intelligence sharing were hamstrung by bureaucratic inertia and a paucity of specialists adept at tracing sophisticated counterfeit supply chains. Equally salient is the scrutiny of municipal public‑health outreach, which, while ostensibly intended to inform residents of emergent drug safety threats, appears to have allocated resources to antiquated communication channels, thereby omitting actionable guidance for the most vulnerable demographics and diminishing the efficacy of citizen warnings. Hence, does the prevailing municipal governance framework possess adequate statutory mechanisms to compel accountability for the identified procedural lapses, or must legislative reform be contemplated to institute transparent audit trails, mandated disclosure of procurement contracts, and enforceable penalties for deviations from verified pharmaceutical standards, thereby restoring public confidence in the city’s health‑safety apparatus?

Moreover, the transnational dimension of the alleged counterfeit enterprise raises the issue of whether existing extradition treaties and mutual legal assistance arrangements between India and the United Arab Emirates afford sufficient procedural clarity to expedite the apprehension and prosecution of overseas offenders implicated in mass fraud against vulnerable patients. In addition, the episode compels scrutiny of the city’s financial oversight bodies, for it remains unclear whether the substantial sums allegedly diverted through fraudulent drug channels were subject to rigorous audit by the municipal treasury, or whether fiscal opacity permitted the covert absorption of public funds into private coffers. Consequently, one must ask whether the existing municipal grievance redressal mechanism, ostensibly designed to afford aggrieved citizens swift recourse, possesses the requisite investigative capacity and independence to substantively evaluate complaints of pharmaceutical malpractice, or whether procedural bottlenecks and limited transparency render it a nominal conduit rather than an effective safeguard. Thus, does the municipal code contain explicit provisions mandating transparent disclosure of all pharmaceutical procurement contracts and the publication of periodic compliance reports, or must a comprehensive legislative overhaul be undertaken to embed accountability, enforce evidence‑based safety standards, and empower ordinary residents to hold local authorities to recorded fact?

Published: May 16, 2026

Published: May 16, 2026